IgA nephropathy pathogenesis and therapy: Review & updates
Authors:
- Elmukhtar HabasEHElmukhtar Habas
- Elrazi Mbbch AliEAElrazi Mbbch Ali
- Khalifa FarfarKFKhalifa Farfar
- Mahdi ErrayesMEMahdi Errayes
- Jamal Mrcp AlfitoriJAJamal Mrcp Alfitori
- Eshrak Mbbch HabasEHEshrak Mbbch Habas
- Hafedh Msc GhazouaniHGHafedh Msc Ghazouani
- Raza Mrcp AkbarRARaza Mrcp Akbar
- Fahim KhanFKFahim Khan
- Aisha Al DabADAisha Al Dab
- Abdel-Naser MBChB ElzoukiAEAbdel-Naser MBChB Elzouki
Open Access
- 2 December 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (48) , e31219
Abstract
Background: IgA nephropathy (IgAN) is the most frequent type of primary glomerulonephritis since the first type was described more than four decades ago. It is the prevalent cause of primary glomerular disease that causes end-stage renal disease. In most patients with IgAN, hematuria is the most common reported symptom, particularly in those with a preceding upper respiratory tract infection. Although the pathogenesis of IgAN is usually multifactorial, autoimmune complex formation and inflammatory processes are the most widely recognized pathogenic mechanisms. Multiple approaches have been trialed as a therapy for IgAN, including tonsillectomy, steroids, other immune-suppressive therapy in different regimens, and kidney transplantation. Aim and method: PubMed, Google, Google Scholar, Scopus, and EMBASE were searched by the authors using different texts, keywords, and phrases. A non-systemic clinical review is intended to review the available data and clinical updates about the possible mechanism(s) of IgAN pathogenesis and treatments. Conclusion: IgAN has a heterogeneous pattern worldwide, making it difficult to understand its pathogenesis and treatment. Proteinuria is the best guide to follow up on the IgAN progression and treatment response. Steroids are the cornerstone of IgAN therapy; however, other immune-suppressive and immune-modulative agents are used with a variable response rate. Kidney transplantation is highly advisable for IgAN patients, although the recurrence rate is high. Finally, IgAN management requires collaborative work between patients and their treating physicians for safe long-term outcomes.Keywords
This publication has 51 references indexed in Scilit:
- The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progressionKidney International, 2012
- Geographic Differences in Genetic Susceptibility to IgA Nephropathy: GWAS Replication Study and Geospatial Risk AnalysisPLOS Genetics, 2012
- Pathogenesis of IgA nephropathyNature Reviews Nephrology, 2012
- Aberrant glycosylation of IgA1 is inherited in both pediatric IgA nephropathy and Henoch–Schönlein purpura nephritisKidney International, 2011
- The pathogenesis of IgA nephropathyCurrent Opinion in Nephrology and Hypertension, 2011
- The IgA nephropathy treatment dilemmaKidney International, 2006
- Is IgA nephropathy the commonest primary glomerulopathy among young adults in the USA?Kidney International, 2006
- Mycophenolate mofetil in IgA nephropathy: Results of a 3-year prospective placebo-controlled randomized studyKidney International, 2004
- Natural history of idiopathic IgA nephropathy: Role of clinical and histological prognostic factorsAmerican Journal of Kidney Diseases, 2000
- Effects of dietary protein restriction on the progression of advanced renal disease in the modification of diet in renal disease studyAmerican Journal of Kidney Diseases, 1996